Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
In the absence of standardized diagnosis and the presence of unique clinical syndromes, it is not surprising that considerable differences exist in the number of reported incidences of disease and the outcomes of various infections in cardiothoracic transplant (CTTX) recipients. Publications to date have employed variable and heterogeneous definitions of CTTX-related infections, thereby limiting the comparison between the types and incidence of infections and the generalizability of these data across transplant centers. Currently, there are no standard international definitions for infections uniquely related to CTTX, with the exception of Chagas disease and toxoplasmosis.1 The purpose of the present working formulation is to provide consensus-derived expert opinion of definitions for infections in CTTX for epidemiologic, research and registry data use.

Scope

Standard definitions of infections specifically related to CTTX will allow for meaningful comparison of the type and incidence of these infections between different types of CTTXs, different regimens of immunosuppression and between different transplant centers, thereby improving the reporting of infection-related morbidity and mortality after cardiothoracic transplantation. The definitions proposed herein are suitable for epidemiologic investigations and are intended to facilitate clinical decision-making.

The definitions described in what follows have been reviewed and approved by a multidisciplinary working group of The International Society for Heart and Lung Transplantation (ISHLT).

Source

These definitions were adapted from surveillance definitions of healthcare-associated sinusitis, tracheobronchitis and pneumonia, used in reporting to the National Healthcare Safety Network (NHSN) and the Centers for Disease Control and Prevention’s (CDC) surveillance system for patient and healthcare personnel safety.2 Definitions of invasive fungal infection (IFI) were based on those proposed by the European Organization for Research and Treatment of Cancer and the Mycoses Study Group of the National Institutes of Health (EORTC/MSG),3 whereas definitions from the American Society of Transplantation and other source documents represented the foundation for defining viral infections.1,4
Bacterial infection overview

All bacterial infections

Bacterial infections are a major contributor of complications in the early post-transplant period in heart- and lung-transplanted patients. Some bacterial infections (e.g., pre-transplant colonization or donor-derived infections) have unique issues and implications in CTTX recipients; therefore, the definitions for these infections for epidemiologic, research or ISHLT registry purposes are specifically addressed herein. Many other bacterial infections (e.g., methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococcus) are present similarly across hospitalized patients and solid-organ transplant (SOT) recipients and are therefore not directly addressed in what follows.

The existing literature in CTTX has largely classified bacterial infections as “early” (e.g., post-operative) or “late” onset after transplantation, allowing transplant clinicians to determine the source of these infections and focus prevention strategy and early empirical antibiotic treatment regimens on the temporal onset of these infections. A further timeline is used to classify all infections diagnosed in the hospital setting as nosocomial, with onset 48 hours after the patient is admitted to the hospital, and community-acquired infection, with onset at the time of admission or within 48 hours of admission. The latter definitions of infection may be artificial in the setting of CTTX as some infections, although related to healthcare and immunosuppression, may not occur within the established time-line of nosocomial infections. To fully appreciate the impact of the potential source of infection, we propose using the categories of nosocomial (after 48 hours

### Table 1a Bacterial Pneumonia and Colonization in CTTX

| Infection | Signs/symptoms | Radiology | Microbiology/pathology | Histopathologic evidence of AR |
|-----------|----------------|-----------|-------------------------|-------------------------------|
| **Proven pneumonia, acute rejection (AR)- associated OR not AR associated** | At least one of the following: ● Fever >38°C or hypothermia <36.5°C with no other recognized cause ● Leukopenia (<4,000 WBC/mm³) or leukocytosis (≥15,000 WBC/mm³) And at least two of the following: ● New-onset of purulent sputum OR change in character/quantity of sputum OR increased respiratory secretions suctioned ● New-onset or worsening cough, dyspnea, tachypnea, OR pleural rub, rales OR bronchial breath sounds ● Worsening gas exchange (O₂ desaturations, PaO₂/FI0₂ ≥240, increased O₂ requirements, increased ventilation demands) ● Pleural effusion | New/worsening radiographic changes on chest X-ray or CT scan | At least one of the following: ● Positive growth in blood culture unrelated to other source ● Positive growth in culture of pleural fluid ● Positive respiratory culture (sputum, bronchial secretions, BAL, bronchial protected sterile brushing) ● ≥5% BAL-obtained cells containing intracellular bacteria on direct microscopic exam | AR may be present or absent or not investigated |
| **Probable pneumonia** | As for proven | As for proven | Negative microbiology PLUS absence of AR by histopathology | AR must be excluded |
| **Possible pneumonia** | As for proven | As for proven | Microbiology negative or not performed PLUS concomitant clinical diagnosis of AR (without histopathology) | No histopathology performed |
| **No pneumonia, proven AR** | As for proven | As for proven | Negative microbiology PLUS AR proven by histopathology | Histopathologic evidence of AR |
| **Colonization** | Asymptomatic OR no significant changes in symptoms; stable PFT; normal bronchoscopy without: ● Endobronchial erythema AND ● Purulent secretions | Absent or unchanged | Recovery of pathogen in absence of clinical or radiographic changes | AR present or absent |

The Journal of Heart and Lung Transplantation, Vol 30, No 4, April 2011
of hospitalization) and community-acquired (prior to 48 hours of hospitalization) with the added category of community-acquired “transplant-related” infections. This category would include infections by pathogens acquired by the CTTX patient prior to time of transplantation and that are clearly related to the immunocompromised state of the CTTX patient after transplantation that may increase the risk for specific bacterial pathogens that are not common in the community. These pathogens may be related to the donor or the recipient via pre-transplant colonization of the respiratory or gastrointestinal (GI) tract and can be therefore regarded as “transplant-related” in this setting.\textsuperscript{12,13} It is also to be noted that community-acquired pneumonia may be transplant-related if caused by organisms that are typically associated with transplants (e.g., fungal, multidrug-resistant or atypical bacteria).

**Respiratory bacterial infections**

Respiratory bacterial infections occur frequently in lung transplant recipients. In one study, 72 episodes per 100 lung transplants per year were reported.\textsuperscript{14} The source of bacteria-causing pneumonia in lung transplant recipients may be the donor, the recipient or the hospital environment. Nosocomial transmission from other patients or healthcare workers can occur when hand hygiene or appropriate respiratory isolation measures for other hospitalized infected patients are not routinely practiced.\textsuperscript{11,15–19}

| Table 1b Bacterial Tracheobronchitis and Bronchial Anastomotic Infections in Lung Transplant Recipients |
|--------------------------------------------------------------------------------------------------|
| Infection | Signs/symptoms | Radiology | Microbiology | Histopathologic evidence |
|------------|----------------|-----------|--------------|-------------------------|
| Proven tracheobronchitis | At least one of the following: ● New-onset purulent sputum OR change in character/quantity of sputum OR increased respiratory secretions suctioned ● New-onset or worsening cough, dyspnea, tachypnea AND ● One or more endobronchial lesions (erythema, ulceration, necrosis and pseudomembrane formation, including at the site endobronchial stent) without an alternative diagnosis and without evidence of invasive parenchymal disease (Figure 1b) | Negative chest X-ray OR one CT scan without the following: ● New/progressive and persistent infiltrate ● Consolidation ● Cavitition May be positive if concurrent pneumonia is present | At least one of the following: ● Positive respiratory culture (sputum, bronchial secretions or tissue, BAL, bronchial protected sterile brushing) | Histology showing inflammation with organisms or positive culture from the sterile tissue ALONE |
| Probable tracheobronchitis | As for proven | As for proven | As for proven | Negative histopathology |
| Proven bronchial anastomotic infection | At least one of the following: ● New-onset purulent sputum OR change in character/quantity of sputum OR increased respiratory secretions suctioned ● New-onset or worsening cough, dyspnea, tachypnea AND endobronchial lesions (erythema, ulceration, necrosis and pseudomembrane formation) restricted to the site of anastomosis without involvement of other parts of bronchial tree or lung parenchyma | As for proven tracheobronchitis; may be positive if concurrent pneumonia is present | As for proven tracheobronchitis | Negative histopathology |
| Probable bronchial anastomotic infection | As for proven | As for proven | As for proven tracheobronchitis | Negative histopathology |
The definitions of bacterial pneumonia present significant challenges in CTTX. Frequent use of empirical anti-bacterial agents prior to specimen collection and the possibility of concurrent allograft rejection make the use of standard guidelines, as presented by the Centers for Disease Control and Prevention (CDC) for healthcare-associated infections (HCAIs), difficult to apply. In addition, some microbiologic diagnostic procedures may not be routinely practiced at many transplant centers and this may limit the employment of diagnostic criteria for infections that require quantification of bacterial colony-forming units per milliliter in the bronchoalveolar lavage (BAL) samples. This methodology has not been validated in the immunocompromised host and is not standardized across institutions. Further, the thresholds proposed may underestimate the episodes of bacterial pneumonia in the CTTX population, where early empirical intervention with anti-microbial agents prior to obtaining the samples with suspected pneumonia is common practice. Presence of endobronchial stents in lung transplant recipients further complicates the picture in defining various clinical syndromes.

For these reasons, a specific classification of bacterial pneumonias in CTTX recipients is proposed based on radiographic findings, clinical symptoms, microbiology and histopathology (including consideration of acute rejection in lung transplant patients).

In lung transplant recipients, the use of differential cytology in BAL may be helpful. The predominance of neutrophils with intracellular bacteria (hematoxylin–eosin and gram stain) is more suggestive of the presence of a bacterial pneumonia than a high proportion of lymphocytes or eosinophils in BAL. On the other hand, a lymphocytic or eosinophilic BAL could indicate an acute graft reaction, although cytomegalovirus (CMV), other viruses and atypical pathogens would need to be ruled out.

Acute rejection (AR) of the graft in lung transplant recipients presents a significant consideration in the diagnosis of all pneumonias, including those due to bacteria. There are frequent clinical scenarios where distinction between rejection and infection is critically dependent upon histopathologic findings. In many cases, evidence for infection and rejection coexist. Therefore, in the setting of lung transplantation, the diagnosis of bacterial (or any) pneumonia is more precisely defined by the confirmation or exclusion of AR when microbiologic criteria are not met.

The determination of AR requires histologic examination. If an AR is documented and clinical and laboratory criteria for bacterial pneumonia are also fulfilled, the diagnosis of AR and concomitant pneumonia is possible. Accordingly, pneumonia should be indicated as pneumonia combined with an AR.

Respiratory bacterial infection diagnostic tools

- Direct examination by light microscopy [gram stain, modified acid-fast bacilli (AFB) stain for Nocardia spp, AFB stains for Mycobacteria].
- Culture (including rapid culture methods for Legionella spp, Mycobacteria spp and prolonged culture periods for detection of bacteria-causing infective endocarditis).
- BAL cell analysis: rule-out contamination with <1% epithelial cells, then quantitative, semi-quantitative or qualitative culture of BAL material or lung biopsy, if available.
- Quantitative, semi-quantitative or qualitative cytology of BAL.
- Histopathology: special staining of lung tissue (if available) for bacteria (i.e., Brown and Brenn stain), Mycobacteria (AFB stain/auramine) and atypical bacteria (Fite stain for Nocardia, etc.).
- Nucleic acid amplification [including polymerase chain reaction (PCR) methods and real-time PCR] methods for atypical respiratory bacteria (Legionella, Chlamydia and Mycoplasma spp).
- Enzyme immunoassays (ELA) antigen tests for pneumococcal and legionella antigens from urine samples.
- Serology (may be useful for research purposes only in select study designs).

Definitions of bacterial pneumonia and colonization in CTTX are given in Table 1a, whereas the definitions of tracheobronchitis are given in Table 1b.

General comments regarding bacterial pneumonia/tracheobronchitis

1. Ventilator-associated pneumonia should be designated when reporting data. A distinction should be made between non-invasive and invasive ventilation.
2. Aspiration pneumonia should be considered if the criteria are fulfilled for pneumonia (Table 1a). The cause of this type of pneumonia should be noted.
3. Multiple or concurrent episodes of post-transplant pneumonia may occur. To determine a new episode in a single patient, resolution of the initial infection must be determined by clinical, laboratory or histologic evidence. The isolation of a new pathogen alone is not indicative of a new episode of pneumonia. In contrast, a second pneumonia may develop in a patient after single lung transplantation. Here, the contralateral lung may develop an “independent” pneumonia by another organism.
4. Sputum samples are frequently contaminated with airway colonizers (e.g., coagulase-negative Staphylococcus and Enterococcus spp), and therefore must be interpreted cautiously.
5. The interferon-gamma release assay (IGRA) serum test is not recommended for diagnosis of acute tracheobronchitis disease, although a positive result is an indication of latent disease or recent infection and a useful screening test if baseline IGRA testing is performed prior to transplantation.
6. Episodes of airway colonization are not recorded as infections.
7. Histologic representation of chronic graft rejection may not impact the diagnosis of bacterial pneumonia. Therefore, it is not included as criteria for pneumonia definition.26

8. The definition of “possible pneumonia” category allows recording of pneumonia after lung transplantation even if required diagnostic procedures were missed, which may occur with prior anti-microbial treatment or delay in diagnostic testing, etc.

9. In lung transplant recipients, it is desirable to always give additional information if evidence of acute graft rejection exists either by clinical or by histopathologic diagnosis.

10. It is possible to have concurrent infections—pneumonia with sinusitis or anastomotic tracheobronchitis.

11. Quantification of organisms in BAL is not considered essential for the diagnosis of ventilator-associated pneumonia (VAP).27 However, invasive diagnostics may help withdraw anti-bacterial therapy, which may prevent further emergence of multi-resistant organisms in future.28,29

12. The category of bacterial tracheobronchitis is classified into probable and proven categories. They can only be diagnosed in the presence of bronchoscopic findings. We have refrained from using the term microbiologically negative tracheobronchitis as it requires more evidence.

13. Endobronchial stent–associated tracheobronchitis or bronchial anastomotic infections, both fungal and bacterial, are categorized as probable (Table 2).

14. No attempt is made to redefine atypical mycobacterial infections or pulmonary tracheobronchitis in lung transplant recipients and the use of existing definitions from European and North American societies are encouraged until further data emerge.30–33

15. It is preferable to document the use of antibiotics in patients with pneumonia at the time of culture data collection.

**Viral infection overview**

**All viral infections**

Cardiothoracic transplant recipients are at an increased risk for viral infections with severe clinical sequelae. Some viral infections have unique considerations and implications in CTTX recipients. The definitions for these viral infections are specifically addressed herein and may be used for epidemiologic, research or registry purposes in CTTX recipients.

Many other non-respiratory viral infections present similarly across SOT recipients. Diagnosis and management of these viral infections have been addressed ade-
quately in other guidelines and therefore will not be addressed herein.

**Respiratory viral infections**

Respiratory viral infections, including newly emerging viruses, occur frequently in lung transplant recipients. Some epidemiologic studies have suggested an association between respiratory viral infection and the development of bronchiolitis obliterans syndrome (BOS). These studies yielded mixed results and the association between respiratory virus infection and BOS remains unclear. The recent availability of molecular diagnostics, including PCR and multiplex gene techniques for the recovery of many viruses simultaneously from a single specimen, increased the recovery of pathogens in respiratory infections that previously were considered to be of undetermined etiology. Other viruses have been identified and are of uncer-

| Infection | Signs/symptoms | Radiology | Microbiology | Histopathologic evidence |
|-----------|----------------|-----------|--------------|--------------------------|
| Ventilator-associated pneumonia (non-invasive or invasive ventilation); patient on ventilator for at least 48 hours continuously | At least one of the following: ● Fever >38°C or hypothermia <36.5°C with no other recognized cause ● Leukopenia (<4,000 WBC/mm³) or leukocytosis (≥11,000 WBC/mm³) And at least two of the following: ● New-onset purulent sputum OR change in character/quantity of sputum OR increased respiratory secretions suctioned ● New-onset or worsening pleural rub, rales OR bronchial breath sounds ● Worsening gas exchange (O₂ desaturations, PaO₂/FIO₂ <240, increased O₂ requirements, increased ventilation demands) | Two or more serial chest radiographs showing new/progressive infiltrate or consolidation OR one CT scan with at least one of the following: ● New/progressive and persistent infiltrate ● Consolidation ● Cavitation | At least one of the following: ● Positive respiratory culture (sputum, bronchial secretions, BAL, bronchial protected sterile brushing), ≥5% BAL-obtained cells containing intracellular bacteria on direct microscopic exam. | Histology (biopsy showing histologic evidence of pneumonia OR positive culture from the sterile tissue ALONE) |
| Endobronchial stent associated: ● Tracheobronchitis ● Bronchial anastomotic infection ● Pneumonia | At least one of the following: ● New-onset purulent sputum OR change in character/quantity of sputum OR increased respiratory secretions suctioned ● New-onset or worsening cough, dyspnea, tachypnea OR pleural rub, rales OR bronchial breath sounds AND endobronchial lesions restricted to the extent of endobronchial stent with or without involvement of anastomosis or other parts of bronchial tree or lung parenchyma | Chest radiograph without: ● New or progressive and persistent infiltrate ● Consolidation ● Cavitation ● Nodules OR CT scan without: ● New or progressive and persistent infiltrate ● Consolidation ● Cavitation ● Nodules | ● Positive respiratory culture (sputum, bronchial secretions, BAL, bronchial protected sterile brushing) ● ≥5% BAL-obtained cells containing intracellular bacteria on direct microscopic exam ● Positive culture for mold/yeast ● OR positive PCR for mold /yeast ● OR positive GM in the BAL OR at least TWO positive sputum cultures/PCRs of fungal organisms (including *Candida* species) | Not applicable |
tain pathogenicity. Further, with the use of molecular diagnostic and deep gene sequencing techniques, novel respiratory viral pathogens, such as human metapneumovirus, human coronaviruses and bocavirus, have been identified. These discoveries have led to the expansion of the repertoire of respiratory viral pathogens and infections to be considered in any research of the impact of respiratory viral infections after CTTX. Characteristic histopathologic changes on lung biopsy specimens when these viruses are present have not been identified by these methods, such as with CMV and herpes simplex virus (HSV), but efforts continue, demonstrating the multidisciplinary approach to the accurate diagnosis of infection in this population. The standardization of diagnosis and categorization of respiratory viral infection is essential for the comprehensive evaluation and generalizability of this growing area of study.

Lower respiratory viral infections (LVRIs) may occur with or without acute rejection. Suspected acute rejection should be looked for if all criteria of LRVIs are fulfilled. CMV in the lung

Definitions for CMV infection and disease, especially for use in research, have been reported in the literature and used in other studies. The methodology for CMV recovery has shifted at many centers over the past decade from conventional viral culture methods and antigenemia toward quantitative molecular diagnostics, including PCR and hybrid

### Table 3a Respiratory Viral Infection in CTTX

| Infection                        | Signs/symptoms                                                                 | Radiology                                      | Virology                                                                 |
|----------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------|
| Respiratory viral infections (RVIs) |                                                                               |                                               |                                                                          |
| Asymptomatic RVI                 | None                                                                          | No changes                                    | Recovery of virus from nasopharynx or bronchoalveolar lavage*             |
| Clinical RVI                     | Two or more of the following:                                                 | Chest radiograph or CT scan not performed     | Lack of confirmatory testing for respiratory viral pathogen (not performed or negative assay) |
|                                  | - Fever >38°C                                                                  |                                              |                                                                          |
|                                  | - Rhinorrhea                                                                   |                                              |                                                                          |
|                                  | - Nasal congestion                                                             |                                              |                                                                          |
|                                  | - Sore throat                                                                  |                                              |                                                                          |
|                                  | - Sneezing                                                                     |                                              |                                                                          |
|                                  | - Chills/rigors                                                                |                                              |                                                                          |
|                                  | - Myalgia                                                                      |                                              |                                                                          |
|                                  | - Headache                                                                    |                                              |                                                                          |
|                                  | **AND** exclusion of other etiology for symptoms including but not limited to recovery of another pathogen or histopathology for acute rejection |                                              |                                                                          |
| Upper respiratory tract infection| As for clinical RVI                                                            | No evidence of lower respiratory tract infection | Confirmation of a respiratory viral pathogen                              |
| Lower respiratory tract infection| Clinical symptoms (two or more of those listed above for URI) **PLUS** one or more of the following symptoms of lower respiratory tract involvement: | New/worsening radiographic changes on chest X-ray or CT scan | Confirmation of a respiratory viral pathogen OR histopathologic evidence **AND** exclusion of AR |
|                                  | - Cough                                                                        |                                              |                                                                          |
|                                  | - Dyspnea                                                                      |                                              |                                                                          |
|                                  | Physical findings (one or more of the following):                             |                                              |                                                                          |
|                                  | - Hypoxia (new onset or increasing)                                            |                                              |                                                                          |
|                                  | - New or increased O₂ requirement                                              |                                              |                                                                          |
|                                  | - New crackles, rales or wheezing                                              |                                              |                                                                          |
|                                  | Acute respiratory distress syndrome                                            |                                              |                                                                          |

*Respiratory viral infection diagnostic tools: nucleic acid amplification (including PCR methods); tissue (cell) culture, both conventional and rapid; culture (shell-vial/R-mix); indirect and direct immunofluorescence antibody (IFA/DFA) tests; and enzyme immunoassays (EIAs).
However, the issues related to the recovery of CMV in BAL fluid in the absence of histopathologic evidence of CMV remain unresolved, and investigations are ongoing to resolve this issue. Asymptomatic viral shedding in the upper oropharynx by CMV is distinguished from active CMV disease in these definitions and will assist in further assessing the role of CMV in CTTX. In early studies, the recovery of CMV by viral culture in the absence of tissue diagnosis was considered diagnostic of CMV pneumonitis. However, further studies did not suggest that CMV recovery from BAL was predictive of subsequent CMV pneumonitis. With the advent of sophisticated molecular diagnostics, the recovery of CMV from BAL became more specific and reproducible compared with conventional or shell-vial culture, and additional studies suggested that CMV viral load in BAL fluid may be correlated with invasive CMV pneumonia.

However, the utility of CMV viral load in BAL in predicting CMV pneumonitis remains uncertain in studies to date.

**CMV diagnostic tools**

- Molecular diagnostics (from whole blood, plasma, BAL or tissue).
  - Quantitative DNA PCR or hybrid capture assays.
  - Qualitative PCR.
  - Genotypic resistance testing.
- Antigen pp65.
- Viral culture (conventional or shell-vial centrifugation).

- In situ immunohistochemistry.
- Serology: not recommended for diagnosis.

Definitions for respiratory viral infections are given in Table 3a and 3b.

**Fungal infection overview**

All fungal infections

CTTX recipients in general and lung transplant recipients in particular have the highest risk of mold infection. Recently published data suggest the cumulative incidence rate at 1 year to be 8%. Among mold infections, the overwhelming majority of infections are due to *Aspergillus* spp, followed by *Scedosporium* spp and zygomycetes. Despite the advancement in anti-fungal therapy, mortality remains at approximately 29% in *Aspergillus* infections. *Candida* species was noted to be a major pathogen during the early CTTX period, although it is rarely seen in lung transplant recipients in the current era. Although the incidence of invasive candidiasis has remained low in lung transplant recipients, this was the most common fungal infection noted in heart transplant recipients.

**Respiratory fungal infections**

Fungal infections in lung transplant recipients have certain characteristics that make them unique compared with other
SOT recipients as well as other immunocompromised hosts. This includes the presence of certain risk factors, such as airway ischemia and native lung or unique clinical syndromes, including tracheobronchitis, bronchial anastomotic infection and colonization—syndromes observed only in lung transplant recipients (Figure 2). Rejection syndromes in lung transplant recipients further complicate the clinical presentation. Diagnosis of fungal infection based on histology alone may not be as accurate due to the concomitant presence of acute or chronic rejection in these individuals. Similarly, it is not only the unique clinical syndromes of fungal infection that set them apart from the other immunocompromised hosts, but the diagnostic utility of non-invasive testing also is different. Serum galactomannan has markedly lower sensitivity (30%) in lung transplant recipients as compared with other immunocompromised hosts. Similarly, the sensitivity of other serologic markers such as serum cryptococcal or coccidiodal antigen, histoplasma urine antigen may be variable. The use of BAL for GM has resulted in sensitivities of >66% when a 0.58 or 0.66 optical density (OD) index was used as a cutoff. A higher cutoff (1.5 OD) yielded better results in one study. We suggest the use of BAL GM in the diagnosis of invasive aspergillosis (IA) in lung transplant recipients. Similarly, fungal PCRs, especially from BAL specimens, are more likely to be less sensitive for the diagnosis of disease than BAL specimens from other immunocompromised hosts owing to colonization of the airways. Cell wall components of fungi have also been used in the diagnosis of fungal infections. Currently available β-D-glucan is non-specific and is negative in cases of cryptococcosis and zygomycosis. In a recent study of lung transplant recipients, serum β-D-glucan sensitivity was reported to be 93%, whereas specificity was merely 71%. The Mycoses Study Group (MSG) and the European Organization for Research and Treatment (EORTC) recently updated the definitions of fungal infections in immunocompromised hosts. These definitions represent an excellent attempt to standardize the reporting of fungal infections in studies. However, they fail to address the unique nature of clinical syndromes in lung transplant recipients, particularly colonization, tracheobronchitis and bronchial anastomotic infections. Also, the radiologic presentation of invasive mycoses in cardiothoracic organ transplant recipients may not conform to the classical “halo sign” presentation in neutropenic or stem

**Table 4a** Fungal Pneumonia in CTTX

| Syndrome | Signs/symptoms | Radiology | Laboratory |
|----------|----------------|-----------|------------|
| **Proven:** | Pneumonia | | |
| Histology (biopsy showing histologic evidence of parenchymal invasion by fungal hyphae or pseudohyphae) or positive culture from sterile tissue ALONE; OR with sign/symptoms + radiology + laboratory | At least one of the following: ● Fever >38°C OR hypothermia <36.5°C with no other recognized cause ● Leukopenia (<4,000 WBC/mm³) OR leukocytosis (≥12,000 WBC/mm³) ● New onset of purulent sputum OR ● Change in character OR quantity of sputum OR respiratory secretions suctioned ● New-onset or worsening cough, dyspnea, tachypnea, or pleural rub, rales or bronchial breath sounds ● Worsening gas exchange (O₂ desaturation, PaO₂/FIO₂ ≤240, increased oxygen requirements or increased ventilation demand) ● Pleural effusion | Chest radiograph with: ● New or progressive and persistent infiltrate ● Consolidation ● Cavitation ● Nodules OR CT scan with at least one of the following: ● New or progressive and persistent infiltrate ● Consolidation ● Cavitation ● Nodules | Single positive culture for mold BAL/blood OR single positive PCR for mold BAL/blood positive galactomannan in the BAL; OR at least TWO positive sputum cultures/PCRs of fungal organisms (excluding Candida species) |
| **Probable:** | Sign/symptoms + radiology + laboratory + negative histology | | |

*In the absence of biopsy categorize as probable: In the presence of histologic findings of both acute rejection and fungal infection it should be classified as acute rejection with proven fungal infection.

*The presence of mosaic appearance and ground-glass opacity may represent development of bronchiolitis obliterans syndrome or obliterative bronchiolitis.

*Isolation of non-pathogenic molds in culture (e.g., Cladosporium spp, Phialoconium, Chaetomium, Cunninghamella, Syncephalastrum, Doctylaria, Graphium or Phialophora) or other non-pathogenic fungi [e.g., Penicillium (non-Marnefi), Paecilomyces or basidiomycetes] do not qualify for the “probable” category. They should only be considered in the “proven” category.
cell transplant recipients (Figure 2). Moreover, the definitions do not account for the differences in the sensitivity of serologic tests, particularly galactomannan in lung transplant recipients. In addition, the category of possible fungal infection might not be applicable in lung transplant recipients owing to a multitude of possible diagnoses in these patients. The American Society of Transplantation (AST) also put forward a set of definitions to be used in the study of these infections in SOT recipients. The AST definitions do take into account some unique clinical syndromes in lung transplant recipients but lack the detailed description of clinical syndromes. Reported studies of fungal infections in lung transplant recipients used diverse definitions. The following sets of definitions are proposed to standardize the reporting of fungal infections, particularly mold and yeast (endemic mycoses, Candida spp and Cryptococcus spp) infections in CTTX recipients, especially among general and lung transplant recipients. The isolation of non-pathogenic molds or other non-pathogenic fungi in BAL or sputum is not believed to satisfy the microbiologic criteria for the diagnosis of probable invasive fungal infections in these patients without histologic confirmation (Tables 4a and 4b). However, these definitions of fungal infections do not address Pneumocystis jiroveci infection, which has previously been adequately defined for use in CTTX.

**Fungal infection diagnostic tools**
- Direct examination by light microscopy (gram, Giemsa and calcofluor stains).
- Culture.
- Histopathology: routine stains (hematoxylin–eosin), special (Gomori methenamine silver, mucicarmine, periodic acid–Schiff), direct immunofluorescence and in situ hybridization).

Histopathologic diagnosis is useful in establishing the diagnosis of endemic fungi because of their distinctive morphology. However, confusion may occur when attempting to differentiate the hyaline molds that commonly cause invasive disease. Fusarium spp and Scedosporium spp cannot be distinguished from Aspergillus spp in tissue sections and even the zygomycetes, which are morphologically quite distinct from Fusarium spp,
Scedosporium spp and Aspergillus spp, have been confused with those organisms. The two most commonly encountered yeasts in tissue section from cardiothoracic transplant recipients, Cryptococcus spp and Candida spp, should be easily distinguished in tissue because of the characteristic round shape of the former. Mucicarmine stain of the capsular material of Cryptococcus spp may further aid in its histopathologic identification.

The presence of mosaic appearance and ground-glass opacity may represent development of bronchiolitis obliterans syndrome or obliterative bronchiolitis.

Table 4b Fungal Tracheobronchitis in CTTX

| Syndrome* | Signs/symptoms | Radiology | Laboratory |
|-----------|----------------|-----------|------------|
| Tracheobronchitis | At least one of the following: | Chest radiograph without: | Single positive culture for mold BAL<sup>3</sup> OR single positive PCR for mold BAL OR positive galactomannan in the BAL OR at least TWO positive sputum cultures/PCRs of fungal organisms (excluding Candida species) |
| Proven: | ● New-onset of purulent sputum OR change in character OR quantity of sputum /respiratory secretions suctioned | ● New or progressive and persistent infiltrate | |
| | ● New-onset or worsening cough, dyspnea, tachypnea or bronchial breath sounds | ● Consolidation | |
| | AND one or more endobronchial lesions (erythema, ulceration, necrosis and pseudomembrane formation including at the site endobronchial stent) without an alternative diagnosis and without evidence of invasive parenchymal disease (Figure 1c) | ● Cavitation | |
| | | ● Nodules | |
| Probable: | | OR CT scan without: | |
| | Sign/symptoms + radiology + laboratory + negative histology | ● New or progressive and persistent infiltrate | |
| | | ● Consolidation | |
| | | ● Cavitation | |
| | | ● Nodules | |

*In the absence of biopsy categorized as probable: In the presence of histologic findings of both acute rejection and fungal invasion it should be classified as acute rejection with proven fungal infection.

Table 4c Fungal Bronchial Anastomotic Infection in Lung Transplant Recipients

| Syndrome* | Signs/symptoms | Radiology | Laboratory |
|-----------|----------------|-----------|------------|
| Bronchial anastomotic infection | At least one of the following: | Chest radiograph without: | Single positive culture for mold BAL<sup>3</sup> OR single positive PCR for mold BAL OR positive galactomannan in the BAL OR at least TWO positive sputum cultures/PCRs of fungal organisms (excluding Candida species) |
| Proven: | ● New onset of purulent sputum OR change in character OR quantity of sputum OR respiratory secretions suctioned | ● New or progressive and persistent infiltrate | |
| | ● New-onset or worsening cough, dyspnea, tachypnea, or bronchial breath sounds | ● Consolidation | |
| | AND endobronchial lesions restricted to the site of anastomosis without clinical or histologic involvement of other parts of bronchial tree or lung parenchyma (Figure 1b) | ● Cavitation | |
| | | ● Nodules | |
| Probable: | | OR CT scan without: | |
| | Sign/symptoms + radiology + laboratory + negative histology | ● New or progressive and persistent infiltrate | |
| | | ● Consolidation | |
| | | ● Cavitation | |
| | | ● Nodules | |

*In the absence of biopsy categorized as probable: In the presence of histologic findings of both acute rejection and fungal invasion it should be classified as acute rejection with proven fungal infection.
• Nucleic acid amplification, including PCR methods and real-time-PCR (e.g., Myc assay available for clinical specimens).
• Enzyme immunoassay (EIA: cryptococcal antigen test, histoplasma antigen test and galactomannan).
• Cell wall component (β-glucan test).

Definitions of fungal pneumonia, tracheobronchitis, bronchial anastomotic infection and colonization in CTTX are given in Tables 4a, 4b, 4c, and 4d, respectively.

Other infectious syndromes in cardiothoracic organ transplant recipients

Non–CTTX-specific infections, such as urinary tract infection (UTI), surgical site infection (SSI), bloodstream infection (BSI), infective endocarditis (IE), *Clostridium difficile* infection (CDI) and skin and soft tissue infections (SSTIs), are not included herein.²,₈₆–₉₄ The consensus opinion of the ISHLT ID council encourages the use of previously published international definitions for these infections, which have been well established outside of the CTTX population. The use of these standard definitions will allow for intercenter comparisons of rates and types of infections that should not be significantly impacted by the transplant.

Disclosure statement

Shahid Husain received grant from Pfizer, Astellas, Merck; Nina Singh received grant from Pfizer; Michael Ison received grants, member of speaking bureau and advisory board member for ADMA, Adamas, BioCryst, Chimerix, GlaxoSmithKlein, Roche, ViraCor, Abbott, Abbott Molecular, Astellas, Biogen Idec; Atul Humar received grant, advisory board member and consultant for Roche, Astellas; Andy Fisher received grant, advisory board member and consultant for Medimmune, GSK, Chiesi, Boehringer Ingelheim; Kate Gould member speaking bureau for Pfizer; Lianne G Singer received grants from Roche, Pfizer, APT; Martha Mooney, Lara Danziger-Isakov, Frauke Mattner, Robin Avery, Robert F. Padera, Leo Lawler, Richard Drew, Amparo Sole, Sean Studer, Patricia Munoz and Margaret Hannan, nothing to disclose.

References

1. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006;6:262-74.
2. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf. Accessed December 3, 2010.
3. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.
4. Ljungh P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7.
5. Mattner F, Fischer S, Weissbrodt H, et al. Post-operative nosocomial infections after lung and heart transplantation. J Heart Lung Transplant 2007;26:241-9.
6. Dauber J, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990;11:291-308.
7. Horvath J, Dummer S, Loyd J, et al. Infection in the transplanted and native lung after single lung transplantation. Chest 1993;104:681-5.
8. Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991;144:552-6.
9. Flume PA, Egan TM, Paradowski LJ, et al. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994;149:1601-7.
10. Frist WH, Loyd JE, Merrill WH, et al. Single lung transplantation: a temporal look at rejection, infection, and survival. Am Surg 1994;60:94-102.
11. Gottlieb J, Mattner F, Weissbrodt H, et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 2009;103:743-9.
12. Mattner F, Kola A, Fischer S, et al. Impact of bacterial and fungal donor organ contamination in lung, heart–lung, heart and liver transplantation. Infection 2008;36:207-12.

13. Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000;356:1307-12.

14. Aguilar-Guisado M, Givalda J, Ussetti P, et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 2007;7:1989-96.

15. Cantrell D, Shamriz O, Cohen MJ, et al. Hand hygiene compliance among physicians: marked heterogeneity due to local culture? Am J Infect Control 2009;37:301-5.

16. Quiros D, Lin S, Larson EL. Attitudes toward practice guidelines among intensive care unit personnel: a cross-sectional anonymous survey. Heart Lung 2007;36:287-97.

17. Sherman M, Middaugh ML, Ross MW. Why healthcare workers don’t wash their hands: a behavioral explanation. Infect Control Hosp Epidemiol 2006;27:484-92.

18. Pittet D, Simon A, Hugonnet S, et al. Hand hygiene among physicians: performance, beliefs, and perceptions. Ann Intern Med 2004;141:1-8.

19. Mattner F, Ruden AS, Mattner L, et al. Thoracic organ transplantation may not increase the risk of bacterial transmission in intensive care units. Int J Hyg Environ Health 2007;210:139-45.

20. Ramirez P, Valencia M, Torres A. Bronchoalveolar lavage to diagnose respiratory infections. Semin Respir Crit Care Med 2007;28:525-33.

21. Mameessier E, Milhe F, Badier M, et al. Comparison of induced sputum and bronchoalveolar lavage in lung transplant recipients. J Heart Lung Transplant 2006;25:523-32.

22. Riise GC, Kjellstrom C, Ryd W, et al. Inflammatory cells and activation markers in BAL during acute rejection and infection in lung transplant recipients: a prospective, longitudinal study. Eur Respir J 1997;10:1742-6.

23. Clelland C, Higenbottam T, Stewart S, et al. Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart–lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expression of HLA-DR and interleukin-2 receptor. Am Rev Respir Dis 1993;147:1386-92.

24. Stewart S, Fishbein MC, Snell GL, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007;26:1229-42.

25. Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007;7:2797-801.

26. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996;15:1-15.

27. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006;355:2619–30.

28. Kwon Y, Milbrandt EB, Yende S. Diagnostic techniques for ventilator-associated pneumonia: conflicting results from two trials. Crit Care 2009;13:303.

29. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000;132:621-30.

30. Chalmerskurlat W, Sood N, Neuuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006;61:507-13.

31. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.

32. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009;48:1657-65.

33. Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009;48:1276-84.

34. Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008;178:876-81.

35. Weinberg A, Zamora MR, Li S, et al. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. J Clin Virol 2002;25:171-5.

36. Milstone AP, Brumble LM, Barnes J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006;28:131-7.

37. Gottlieb J, Schulz TF, Welte T, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009;87:1530-7.

38. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005;5:2031-6.

39. Khalilaf AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004;170:181-7.

40. Engelmann I, Welte T, Fuhrer T, et al. Detection of Epstein–Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol 2009;45:47-53.

41. Weinberg A, Hodges TN, Li S, et al. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol 2000;38:768-72.

42. Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010;89:1028-33.

43. Jartti T, van den HB, Garofalo RP, et al. Metapneumovirus and acute wheezing in children. Lancet 2002;360:1393-4.

44. Kesebir D, Vazquez M, Weibel C, et al. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J Infect Dis 2006;194:1276-82.

45. Maurer JR, Tullis DE, Scavuzzo M, et al. Cytomegalovirus infection in isolated lung transplantations. J Heart Lung Transplant 1991;10:647-9.

46. Bailey TC, Buller RS, Ettinger NA, et al. Quantitative analysis of cytomegalovirus viremia in lung transplant recipients. J Infect Dis 1995;171:1006-10.

47. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Am Rev Respir Dis 1993;147:1017-23.

48. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-95.

49. Gutierrez CA, Chararro C, Krajden M, et al. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998;113:924-32.

50. Solans EP, Yong S, Husain AN, et al. Bronchiolalveolar lavage in the diagnosis of CMV pneumonitis in lung transplant recipients: an immunocytochemical study. Diagn Cytopathol 1997;16:350-2.

51. Riise GC, Andersson R, Bergstrom T, et al. Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest 2000;118:1653-60.

52. Stephan F, Fajac A, Grenet D, et al. Predictive value of cytomegalovirus DNA detection by polymerase chain reaction in blood and bronchoalveolar lavage in lung transplant patients. Transplantation 1997;63:1430-5.

53. Chemaly RF, Yen-Lieberman B, Chapman J, et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant 2005;5:544-8.

54. Chemaly RF, Yen-Lieberman B, Castilla EA, et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage during acute rejection and infection in lung transplant recipients. Am J Transplant 2005;5:544-8.
55. Zedtwitz-Liebenstein K, Jaksch P, Burgmann H, et al. Evaluation of interleukin-6 and interleukin-10 in lung transplant patients with human cytomegalovirus infection. Clin Transplant 2009;23:687-91.

56. Westall GP, Michaelides A, Williams TJ, et al. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004;190:1076-83.

57. Bewig B, Haacke TC, Tiroke A, et al. Detection of CMV pneumonitis after lung transplantation using PCR of DNA from bronchoalveolar lavage cells. Respiratation 2000;67:166-72.

58. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis 2002;4(suppl 3):24-31.

59. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010;50:1101-11.

60. Pasqualotto AC, Xavier MO, Sanchez LB, et al. Diagnosis of galactomannan antigen in solid organ transplant recipients. Transpl Infect Dis 2010;12:220-9.

61. Hadjiliadis D, Howell DN, Davis RD, et al. Anastomotic infections in lung transplant recipients. Ann Transplant 2000;5:13-9.

62. Husain S. Unique characteristics of fungal infections in lung transplant recipients. Clin Chest Med 2009;30:307-13.

63. Husain S, Kwak EJ, Obman A, et al. Prospective assessment of *Platelia Aspergillus* galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004;4:796-802.

64. Pfleiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-27.

65. Singh N, Alexander BD, Lorholary O, et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008;46:e12-8.

66. Hage C, Kleiman MB, Wheat LJ. Histoplasmosis in solid organ transplant recipients. Clin Infect Dis 2010;50:122-3.

67. Cuellar-Rodriguez J, Avery RK, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010;12:220-9.

68. Assi MA, Binninger MJ, Wengenack NL, et al. Disseminated coccidioidomycosis in a liver transplant recipient with negative serology: use of polymerase chain reaction. Liver Transpl 2006;12:1290-2.

69. Husain S, Clancy CJ, Nguyen MH, et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of *Aspergillus* galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 2008;15:1760-3.

70. Husain S, Paterson DL, Studer SM, et al. *Aspergillus* galactomannan antigen in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007;83:1330-6.

71. Passqualotto AC, Xavier MO, Sanchez LB, et al. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. Transplantation 2010;90:306-11.

72. Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1,3/1,6)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005;43:5957-62.

73. Alexander BD, Smith PB, Davis RD, et al. The (1,3/1,6)-beta-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010;48:4083-8.

74. Nunley DR, Ohori P, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998;114:1321-9.

75. Nunley DR, Gal AA, Vega JD, et al. Saprothetic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest 2002;122:1185-91.

76. Singh N, Husain S. *Aspergillus* infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003;22:258-66.

77. Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007;45:1759-65.

78. Husain S, Kwak EJ, Obman A, et al. Prospective assessment of *Platelia Aspergillus* galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004;4:796-802.

79. Weigt SS, Elashoff RM, Huang C, et al. *Aspergillus* colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009:9:1903-11.

80. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009:9:2085-91.

81. Sole A, Morant P, Salavert M, et al. *Aspergillus* infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005;11:359-65.

82. Sole A, Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med 2009;15:243-53.

83. Arthurs SK, Eid AJ, Deziel PJ, et al. The impact of invasive fungal diseases on survival after lung transplantation. Clin Transplant 2010;24:341-8.

84. Vance AM. The use of the mucicarmine stain for a rapid presumptive identification of *Cryptococcus* from culture. Am J Med Technol 1961;27:125-8.

85. Lopez J, Revilla A, Vilacosta I, et al. Definition, clinical profile, microbiological spectrum, and prognostic factors of early-onset prosthetic valve endocarditis. Eur Heart J 2007;28:760-5.

86. Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005;33:1538-48.

87. Cicalini S, Puro V, Angeletti C, et al. Broadened definition for hospital-acquired infective endocarditis. Clin Infect Dis 2004;39:1084-5.

88. Cecchi E, Parrini I, Chinaglia A, et al. New diagnostic criteria for infective endocarditis. A study of specificity and sensitivity. Eur Heart J 1997;18:1149-56.

89. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med 1994;96:200-9.

90. McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of *Clostridium difficile*-associated disease. Infect Control Hosp Epidemiol 2007;28:140-5.

91. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45.

92. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64.

93. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406.